Eurofins Scientific 将来の成長

Future 基準チェック /36

Eurofins Scientific利益と収益がそれぞれ年間18.3%と7.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に11.4% 17.9%なると予測されています。

主要情報

18.3%

収益成長率

17.9%

EPS成長率

Life Sciences 収益成長	26.2%
収益成長率	7.3%
将来の株主資本利益率	11.4%
アナリストカバレッジ	Good
最終更新日	13 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

WBAG:ESF - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	8,069	608	792	1,479	13
12/31/2025	7,500	506	679	1,339	14
12/31/2024	6,949	413	583	1,190	11
6/30/2024	6,724	326	674	1,215	N/A
3/31/2024	6,619	291	571	1,117	N/A
12/31/2023	6,515	257	468	1,018	N/A
9/30/2023	6,512	335	403	995	N/A
6/30/2023	6,510	414	339	971	N/A
3/31/2023	6,611	497	407	1,054	N/A
12/31/2022	6,712	581	476	1,136	N/A
9/30/2022	6,785	612	602	1,219	N/A
6/30/2022	6,857	643	727	1,301	N/A
3/31/2022	6,787	696	866	1,406	N/A
12/31/2021	6,718	749	1,005	1,511	N/A
9/30/2021	6,553	786	1,023	1,499	N/A
6/30/2021	6,388	824	1,041	1,487	N/A
3/31/2021	5,913	665	955	1,355	N/A
12/31/2020	5,439	505	868	1,224	N/A
9/30/2020	5,079	347	713	1,057	N/A
6/30/2020	4,719	190	558	891	N/A
3/31/2020	4,641	168	457	784	N/A
12/31/2019	4,563	146	355	678	N/A
9/30/2019	4,384	144	300	618	N/A
6/30/2019	4,205	143	244	558	N/A
3/31/2019	3,993	159	212	551	N/A
12/31/2018	3,781	175	180	544	N/A
9/30/2018	3,549	182	179	521	N/A
6/30/2018	3,318	190	178	498	N/A
3/31/2018	3,145	185	N/A	451	N/A
12/31/2017	2,971	179	N/A	405	N/A
9/30/2017	2,848	166	N/A	387	N/A
6/30/2017	2,725	152	N/A	369	N/A
3/31/2017	2,631	145	N/A	370	N/A
12/31/2016	2,537	138	N/A	372	N/A
9/30/2016	2,427	104	N/A	350	N/A
6/30/2016	2,317	69	N/A	328	N/A
3/31/2016	2,133	63	N/A	310	N/A
12/31/2015	1,950	56	N/A	291	N/A
9/30/2015	1,779	71	N/A	274	N/A
6/30/2015	1,609	86	N/A	256	N/A
3/31/2015	1,509	82	N/A	234	N/A
12/31/2014	1,410	78	N/A	212	N/A
9/30/2014	1,355	66	N/A	187	N/A
6/30/2014	1,299	53	N/A	162	N/A
3/31/2014	1,262	53	N/A	166	N/A
12/31/2013	1,226	53	N/A	169	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ESFの予測収益成長率 (年間18.3% ) は貯蓄率 ( 1.4% ) を上回っています。

収益対市場: ESFの収益 ( 18.3% ) はAustrian市場 ( 8.8% ) よりも速いペースで成長すると予測されています。

高成長収益: ESFの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: ESFの収益 ( 7.3% ) Austrian市場 ( 0.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: ESFの収益 ( 7.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ESFの自己資本利益率は、3年後には低くなると予測されています ( 11.4 %)。

Eurofins Scientific 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024

Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027

Eurofins Scientific SE Revised Earnings Guidance for the Fiscal 2022

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2023 and 2024

Recent updates

Eurofins Scientific SE to Report First Half, 2025 Results on Jul 24, 2025

Eurofins Scientific SE to Report Fiscal Year 2024 Results on Feb 26, 2025

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).

Investor sentiment deteriorates as stock falls 15%

Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited.

First half 2024 earnings released: EPS: €1.15 (vs €0.65 in 1H 2023)

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024

Dividend of €0.50 announced

Insufficient new directors

Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC.

Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: €1.61 (vs €3.02 in FY 2022)

New minor risk - Profit margin trend

First half 2023 earnings released: EPS: €0.79 (vs €1.52 in 1H 2022)

Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027

Upcoming dividend of €1.00 per share at 1.8% yield

Now 22% undervalued after recent price drop

Eurofins Scientific SE to Report First Half, 2023 Results on Jul 26, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: €3.16 (vs €3.91 in FY 2021)

Now 20% undervalued after recent price drop

Eurofins Scientific SE to Report Fiscal Year 2022 Results on Feb 21, 2023

Eurofins Scientific SE to Report Q3, 2022 Results on Oct 18, 2022

Now 22% undervalued after recent price drop

Eurofins Scientific SE (ENXTPA:ERF) signed of an agreement to acquire unknown majority stake in QSAI Analysis and Research Center Co., Ltd.

Eurofins Scientific SE (ENXTPA:ERF) acquired Wessling Hungary Kornyezetvedelmi, Elelmiszerbiztonsagi, Egeszsegvedelmi Es Minosegugyi Sz.

First half 2022 earnings released: EPS: €1.62 (vs €2.09 in 1H 2021)

Eurofins Scientific SE Revised Earnings Guidance for the Fiscal 2022

Upcoming dividend of €1.00 per share

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire unknown majority stake in Ajal for Laboratories from Saudi Ajal Laboratories.

Eurofins Scientific SE (ENXTPA:ERF) acquires an unknown majority stake in Repertoire Genesis Inc.

Health Canada Approves Eurofins CDMO Alphora Inc.’s Standard Processing License for Synthetic Phytocannabinoids

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2023 and 2024

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Eurofins Scientific SE to Report Q1, 2022 Results on Apr 21, 2022

Eurofins’ empowerDX Launches PFAS Exposure™ in the U.S, the First at-Home Blood Test to Detect and Measure 40+ PFAS Compounds

Eurofins Technologies Launches New Lateral Flow Reader Rapidscan ST5-W as Single Platform Validated for Multiple Food and Environmental Rapid Tests

Eurofins Scientific SE (ENXTPA:ERF) entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. (TSE:2342).

Eurofins Technologies Launches New Multiplex RT-PCR Respiratory Panel for SARS-CoV-2, Flu A, Flu B, RSV A and RSV B

First half 2021 earnings released: EPS €2.17 (vs €0.43 in 1H 2020)

Eurofins Scientific SE (ENXTPA:ERF) acquired bioskin GmbH.

Eurofins Launches a New Multiplex PCR Assay for Rapid Detection of the B.1.617 India Sars-Cov-2 Variant

Eurofins Scientific Adds Virus Variant Detection to its SARS-CoV-2 Monitoring Solution for Wastewater, Surface, Air and Worn Masks

Full year 2020 earnings released: EPS €2.71 (vs €0.82 in FY 2019)

Revenue beats expectations

Eurofins Environment Testing America Expands Reporting to 75 Compounds

Eurofins Scientific SE to Report Fiscal Year 2020 Results on Mar 01, 2021

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire Beacon Discovery, Inc.

Eurofins Adds Virus Variant Distinction to its Sars-Cov-2 Monitoring Solution for Wastewater, Food and Environmental Surfaces

Eurofins Launches New Ultra-Fast Extraction-Free RT-PCR Method and Upgrades its RT-PCR Assay for Use with Pharynx Gargle and Saliva Sample Matrices

New 90-day high: €80.51

New 90-day high: €73.16

Eurofins Genomics Launches Cost-Effective SARS-CoV-2 Full-Length Viral Genome Sequencing Services Essential in the Identification of Viral Mutations

Eurofins U.S. Clinical Diagnostic Laboratories At-Home COVID-19 Test Now Being Offered in All 50 States

Eurofins Technologies Launches New and Improved Lateral Flow Device Product Line for Allergen Detection in Foodstuffs and Environmental Samples

Eurofins Scientific SE (ENXTPA:ERF) acquired Taiyo Techno Research.

Eurofins Launches Sensitive, Fast and Cost-effective High Throughput SARS-CoV-2 Test Kits for Widely Available Sanger Sequencing Equipment

Eurofins U.S. Clinical Diagnostics Network Receives EUA Approval of At Home COVID-19 Test

Eurofins Scientific Se Launches Europe’S First Validated Test Method to Evaluate Filtration Capacity of Masks for Sars-Cov-2

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘